+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Immunoglobulin therapy in Kawasaki syndrome and RSV prophylaxis



Immunoglobulin therapy in Kawasaki syndrome and RSV prophylaxis



Frontiers in Bioscience 1: E55-E64



Kawasaki syndrome and RSV infection are common illnesses that afflict infants and young children. Recent studies demonstrate that intravenous immunoglobulin (IVIG) treatment significantly reduces the clinical severity of these illnesses. The purpose of the current review will be initially to examine mechanisms of disease pathogenesis in KS and RSV infection. This will be followed by a discussion of the potential mechanisms by which IVIG acts in these two illnesses. In both KS and RSV prophylaxis, an important action by which IVIG may work is primarily through toxin or microbial neutralization resulting in the dampening or prevention of the inflammatory response. Other immunomodulatory actions of IVIG are likely to be operative in these diseases and will be an active area of future research.

(PDF emailed within 1 workday: $29.90)

Accession: 008819638

Download citation: RISBibTeXText

PMID: 9159245


Related references

Mechanisms of immunoglobulin action: observations on Kawasaki syndrome and RSV prophylaxis. Immunological Reviews 139: 109-123, 1994

Severe dyshidrotic eczema after intravenous immunoglobulin therapy for Kawasaki syndrome. Pediatric Dermatology 30(3): E30-E31, 2014

Immunoglobulin G values before treatment are correlated with the responsiveness to initial intravenous immunoglobulin therapy for Kawasaki disease. International Archives of Allergy and Immunology 164(2): 83-88, 2014

On prophylaxis and therapy with human immunoglobulin preparations Report of the 12th Convention of the German Society for Blood Transfusion Immunological principles of hemo-therapy, aimed hemotherapy ; prophylaxis of transfusion hepatitis; prophylaxis Rh-sensibilization, 31 May - 3 June, 1966, Basel, Switz. Bibl Haematol: 9-252, 1967

Correlates of Defaulting from MDT among Leprosy Patients. Indian Journal of Leprosy 87(4): 241-248, 2018

Steroid pulse therapy for Kawasaki disease unresponsive to additional immunoglobulin therapy. Paediatrics & Child Health 16(8): 479-484, 2012

Immunoglobulin in treatment of Kawasaki syndrome. Lancet 342(8880): 1172-1172, 1993

Steroid pulse therapy for children with intravenous immunoglobulin therapy-resistant Kawasaki disease: a prospective study. Pediatric Cardiology 34(4): 959-963, 2013

Kawasaki disease resistant to immunoglobulin G therapy. Annals of Tropical Paediatrics 23(3): 187-191, 2003

Intravenous immunoglobulin in Kawasaki syndrome: a progress report. Pediatric Infectious Disease 5(3 Suppl): S211-S215, 1986

Recommendations for intravenous immunoglobulin therapy of Kawasaki disease. Pediatric Infectious Disease Journal 11(11): 985-986, 1992

Predictors of nonresponse to intravenous immunoglobulin therapy in Kawasaki disease. Korean Journal of Pediatrics 56(2): 75-79, 2013

The immunomodulatory effects of intravenous immunoglobulin therapy in Kawasaki disease. Expert Review of Clinical Immunology 11(7): 819-825, 2016

Kawasaki disease and parvovirus B19 antibody Role of immunoglobulin therapy. Kato, H. International Congress Series; Kawasaki Disease. 170-173, 1995

IL-1, IL-6 and TNFa activity in children with Kawasaki syndrome before and after treating with intravenous immunoglobulin. 9TH INTERNATIONAL CONGRESS OF IMMUNOLOGY [Author] The 9th International Congress of Immunology : 434, 1995